Advertisement
Advertisement
U.S. markets close in 3 hours 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioLineRx Ltd. (BLRX.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Add to watchlist
61.30-0.80 (-1.29%)
At close: 5:24PM IDT
Advertisement
Sign in to post a message.
  • J
    Jon Henry
    I see a buyout in the future for this company, in the least a partnership with a larger biotech company. Their Phase III results were outstanding, now its just a waiting game.
  • W
    William
    BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Global Health Economics and Outcomes Research (HEOR) team of IQVIA, and was a pre-planned study conducted in parallel with the GENESIS Phase 3 trial. These results, together with the highly significant and clinically meaningful data from the GENESIS trial, strongly support the potential use of Motixafortide, on top of G-CSF, as the standard of care in SCM for ASCT.

    The study concluded that the addition of Motixafortide to G-CSF (the current standard of care) is associated with a statistically significant decrease in health resource utilization (HRU) during the ASCT process, compared to G-CSF alone. Based on the significantly higher number of mobilized cells and the lower number of apheresis sessions, lifetime estimates show quality-adjusted-life-year (QALY) benefits and net cost savings of ~$17,000 (not including the cost of Motixafortide), versus G-CSF alone. The study findings, combined with model estimates, suggest that the use of Motixafortide, on top of G-CSF, as the standard of care in mobilization for ASCT, could be a cost-effective option in the US, based on accepted willingness-to-pay (WTP) values for healthcare payers.

    "The compelling cost savings identified by this rigorously designed study strongly support the Company's view that Motixafortide, in combination with G-CSF, can become the new standard of care as an upfront, or primary, therapy for all multiple myeloma patients undergoing autologous stem cell transplantation," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Based on data from the GENESIS trial showing that nearly 90% of patients collected an optimal number of cells for transplantation following a single administration of Motixafortide and in only one apheresis session, versus less than 10% for G-CSF alone, the pharmacoeconomic study demonstrates that use of Motixafortide on top of G-CSF can save $17,000 per patient, not including the cost of Motixafortide. These cost savings should leave substantial room in the future to optimize our pricing strategy for Motixafortide at product launch and thereafter, if approved.

    "It is also important to note that fewer administrations and apheresis sessions confer meaningful safety and time benefits to patients. In addition, the significantly higher median number of cells collected in one apheresis session – ~11 million using Motixafortide on top of G-CSF versus ~2 million for G-CSF alone – not only enables transplantation of an optimal number of cells, with the potential to significantly save on time to engraftment, it also permits the retention of enough cells for cryopreservation in the event that an additional transplantation is required in the future. Lastly, higher levels of certainty regarding the number of apheresis sessions required for mobilization could enable more efficient utilization of apheresis units at transplantation institutions, where there is often a shortage of available machines.

    "We believe the data from the GENESIS study, together with the results from this pharmacoeconomic study, set Motixafortide apart from all other mobilization agents either currently available or in development. If approved, Motixafortide represents a significant advancement in SCM to the benefit of patients and payers alike, and, to that end, we remain on track to submit a New Drug Application (NDA) to the FDA in the first half of next year," Mr. Serlin concluded.
  • A
    American
    BLRX up four percent on the TASE Monday trading day today.
    Bullish
  • H
    History101
    if you have a year, then this is a good stock for you. patience will pay off. look at their incredible results, and look at the 6mo chart, very solid base in the mid $2s. I have my position at $2.70 & plan to hold long term until the sp is $10 or more.
  • d
    dp3350
    Has there been some bad news that has leaked? Down 5.5% now when it was up at the market open. No published news to account for the sell off.
  • A
    American
    There really aren't any shorts left holding BLRX. It was reported last week that BLRX short positions declined 35 percent, from 291,000 shares down to 190,000 shares.

    This amounts to less than one day to cover.

    There are probably a handful of of people playing a range but no solid interest in BLRX until news comes out. Why anyone would be playing BLRX is hoping for news until it doesn't happen and the washes/repeats hoping to be in at the right time.

    I suspect some news late Nov early Dec as that is what was promised. I would like to hear more about the cost analysis benefit being worked up before then however.

    And hopefully good news will be forthcoming concerning the other trials in progress.

    The company has set themselves up to benefit quite well when the SP increases as they can sell their ADR's and capitalize on the good fortune beyond any revenue stream realized with any FDA approval.
  • E
    Eduard
    Since 5 months invested here and will not sell under 10$. Good news today but great news will follow
    Bullish
  • e
    eitan
    Something will happen soon there is same talks with optinal partners
    Bullish
  • S
    SH
    BLRX is worth way more than what retail day traders are peddling it for right now.
  • R
    Royco
    The comprehensive Win should allow for SP to launch …ADR policy announced recently will further benefit stockholders and allow for greater appreciation sooner than many naysayers wrongfully denied..

    “ BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

    10/13/21, 8:30 AM
    TEL AVIV, Israel, Oct. 13, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Global Health Economics and Outcomes Research (HEOR) team of IQVIA, and was a pre-planned study conducted in parallel with the GENESIS Phase 3 trial. These results, together with the highly significant and clinically meaningful data from the GENESIS trial, strongly support the potential use of Motixafortide, on top of G-CSF, as the standard of care in SCM for ASCT.

    The study concluded that the addition of Motixafortide to G-CSF (the current standard of care) is associated with a statistically significant decrease in health resource utilization (HRU) during the ASCT process, compared to G-CSF alone. Based on the significantly higher number of mobilized cells and the lower number of apheresis sessions, lifetime estimates show quality-adjusted-life-year (QALY) benefits and net cost savings of ~$17,000 (not including the cost of Motixafortide), versus G-CSF alone. The study findings, combined with model estimates, suggest that the use of Motixafortide, on top of G-CSF, as the standard of care in mobilization for ASCT, could be a cost-effective option in the US, based on accepted willingness-to-pay (WTP) values for healthcare payers.

    "The compelling cost savings identified by this rigorously designed study strongly support the Company's view that Motixafortide, in combination with G-CSF, can become the new standard of care as an upfront, or primary, therapy for all multiple myeloma patients undergoing autologous stem cell transplantation," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Based on data from the GENESIS trial showing that nearly 90% of patients collected an optimal number of cells for transplantation following a single administration of Motixafortide and in only one apheresis session, versus less than 10% for G-CSF alone, the pharmacoeconomic study demonstrates that use of Motixafortide on top of G-CSF can save $17,000 per patient, not including the cost of Motixafortide. These cost savings should leave substantial room in the future to optimize our pricing strategy for Motixafortide at product launch and thereafter, if approved.

    "It is also important to note that fewer administrations and apheresis sessions confer meaningful safety and time benefits to patients. In addition, the significantly higher median number of cells collected in one apheresis session – ~11 million using Motixafortide on top of G-CSF versus ~2 million for G-CSF alone – not only enables transplantation of an optimal number of cells, with the potential to significantly save on time to engraftment, it also permits the retention of enough cells for cryopreservation in the event that an additional transplantation is required in the future. Lastly, higher levels of certainty regarding the number of apheresis sessions required for mobilization could enable more efficient utilization of apheresis units at transplantation institutions, where there is often a shortage of available machines.

    "We believe the data from the GENESIS study, together with the results from this pharmacoeconomic study, set Motixafortide apart from all other mobilization agents either currently available or in development. If approved, Motixafortide represents a significant advancement in SCM to the benefit of patients and payers alike, and, to that end, we remain on track to submit a New Drug Application (NDA) to the FDA in the first half of next year," Mr. Serlin concluded.

    Gltlongs
  • H
    History101
    per yahoo, this $165 million market cap company has $65 million in cash....
  • K
    Kevin
    Eric, here is your answer to why?

    BioLineRx Ltd. (NASDAQ: BLRX) is a biopharmaceutical firm specializing in oncology. The company is seventh on our list of 11 best stocks for long term growth
    On May 4, investment advisory Maxim kept a Buy rating on BioLineRx Ltd. (NASDAQ: BLRX) stock and raised the price target to $10 from $5, following announcement of top-line results from the company.
    In May, BioLineRx Ltd. (NASDAQ: BLRX) reported convincing results from the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization in patients suffering from multiple myeloma. In response to the positive results, the stock rocketed over 100%. The company is trying to submit a non-disclosure agreement (NDA). If approved the company will have a commercial stage molecule in stem cell mobilization (SCM
  • K
    Kevin
    Mosha has spoken. We are good. Going up today. Guaranteed GREEN
  • C
    CHARLES
    IT doesnt make any sense with great news and the stock has
    no movement.I CURRENTLY HOLD 30000 SHARES AT A
    COST BASIS OF 2.70.WILLING TO WAIT 6MONTHS.
  • d
    dubi
    Inching up
  • R
    Rambo
    What is wrong with this stock?
  • K
    Kevin
    Starting to accumulate more shares on any dips as we head to NOV/DEC and expected updates. Announcement of filing and partnership deal at least expected. Buyout offers could start but think this happens in 2022 after further news on other pipeline candidates.
  • H
    History101
    a good day, continuing on positive trend...
  • D
    Dave R
    someone big still wants to keep this at $3 - what gives?
Advertisement
Advertisement